BR0313942A - Derivados de benzimidazol úteis como agentes antiproliferativos - Google Patents

Derivados de benzimidazol úteis como agentes antiproliferativos

Info

Publication number
BR0313942A
BR0313942A BR0313942A BR0313942A BR0313942A BR 0313942 A BR0313942 A BR 0313942A BR 0313942 A BR0313942 A BR 0313942A BR 0313942 A BR0313942 A BR 0313942A BR 0313942 A BR0313942 A BR 0313942A
Authority
BR
Brazil
Prior art keywords
formula
compounds
antiproliferative agents
benzimidazole derivatives
derivatives useful
Prior art date
Application number
BR0313942A
Other languages
English (en)
Other versions
BRPI0313942B8 (pt
BRPI0313942B1 (pt
BRPI0313942C1 (pt
Inventor
John Charles Kath
Joseph Peter Lyssikatos
Huifen Faye Wang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0313942A publication Critical patent/BR0313942A/pt
Publication of BRPI0313942B1 publication Critical patent/BRPI0313942B1/pt
Publication of BRPI0313942B8 publication Critical patent/BRPI0313942B8/pt
Publication of BRPI0313942C1 publication Critical patent/BRPI0313942C1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

"DERIVADOS DE BENZIMIDAZOL úTEIS COMO AGENTES ANTIPROLIFERATIVOS". A invenção refere-se com compostos de fórmula 1 e sais, pró-drogas e solvatos farmaceuticamente aceitáveis destes, em que R^ 1^, R^ 2^, R^ 3^, e R^ 4^ são como definidos aqui. A invenção também refere-se com métodos de tratar crescimento celular anormal, tal como câncer, em mamíferos pela administração de compostos de fórmula 1 e com composições farmacêuticas para tratar tais distúrbios que contêm os compostos de fórmula 1. A invenção também refere-se com métodos de preparar os compostos de fórmula 1.
BRPI0313942A 2002-08-28 2003-08-14 derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas BRPI0313942C1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40652402P 2002-08-28 2002-08-28
US60/406,524 2002-08-28
US41704702P 2002-10-08 2002-10-08
US60/417,047 2002-10-08
PCT/IB2003/003634 WO2004020431A2 (en) 2002-08-28 2003-08-14 Novel benzoimidazole derivatives useful as antiproliferative agents

Publications (4)

Publication Number Publication Date
BR0313942A true BR0313942A (pt) 2005-07-12
BRPI0313942B1 BRPI0313942B1 (pt) 2019-06-04
BRPI0313942B8 BRPI0313942B8 (pt) 2020-08-04
BRPI0313942C1 BRPI0313942C1 (pt) 2021-05-25

Family

ID=31981411

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0313942A BRPI0313942C1 (pt) 2002-08-28 2003-08-14 derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas

Country Status (41)

Country Link
US (1) US7071337B2 (pt)
EP (1) EP1594858B1 (pt)
JP (1) JP4551771B2 (pt)
KR (2) KR20070086768A (pt)
CN (1) CN1319966C (pt)
AP (1) AP2005003237A0 (pt)
AR (1) AR041055A1 (pt)
AT (1) ATE445610T1 (pt)
AU (1) AU2003250499B2 (pt)
BR (1) BRPI0313942C1 (pt)
CA (1) CA2495577C (pt)
CR (1) CR7698A (pt)
CU (1) CU23413B7 (pt)
CY (1) CY1110580T1 (pt)
DE (1) DE60329715D1 (pt)
DK (1) DK1594858T3 (pt)
DO (1) DOP2003000694A (pt)
EA (1) EA008448B1 (pt)
EC (1) ECSP055633A (pt)
ES (1) ES2333219T3 (pt)
GE (1) GEP20064005B (pt)
HK (1) HK1078571A1 (pt)
HN (1) HN2003000257A (pt)
HR (1) HRP20050191B1 (pt)
IL (1) IL166832A (pt)
IS (1) IS2738B (pt)
MA (1) MA27389A1 (pt)
MX (1) MXPA05001256A (pt)
MY (1) MY139357A (pt)
NO (1) NO20051303L (pt)
NZ (1) NZ538427A (pt)
OA (1) OA12916A (pt)
PA (1) PA8580301A1 (pt)
PE (1) PE20050131A1 (pt)
PL (1) PL377678A1 (pt)
PT (1) PT1594858E (pt)
RS (1) RS20050180A (pt)
SI (1) SI1594858T1 (pt)
TW (1) TW200407131A (pt)
UY (1) UY27952A1 (pt)
WO (1) WO2004020431A2 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1641780T3 (da) * 2003-06-24 2009-02-02 Pfizer Prod Inc Fremgangsmåder til fremstilling af 1-[(benzimidazol-1yl)quinolin-8-yl]-piperidin-4-ylamin-derivater
BRPI0509580A (pt) * 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
CA2582479C (en) * 2004-10-07 2011-07-12 Pfizer Products Inc. Benzoimidazole derivatives useful as antiproliferative agents
BRPI0608096A2 (pt) 2005-04-26 2009-11-10 Pfizer anticorpos p-caderina
UA94060C2 (ru) 2005-09-07 2011-04-11 Эмджен Фримонт Инк. Моноклональное антитело, которое специфически связывает alk-1
EA200802058A1 (ru) 2006-05-09 2009-06-30 Пфайзер Продактс Инк. Производные циклоалкиламинокислот и их фармацевтические композиции
BRPI0809998B8 (pt) 2007-04-03 2021-05-25 Array Biopharma Inc composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina quinase, seus usos, seus processos de preparação e composições farmacêuticas
MX2010012718A (es) * 2008-05-21 2011-04-04 Incyte Corp Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b ][1,2,4] triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
CA2809892C (en) 2010-09-02 2019-05-28 Merck Patent Gmbh Pyrazolopyridinone derivatives as lpa receptor antagonists
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
JP6407504B2 (ja) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドArog Pharmaceuticals,Inc. 恒常的に活性であるリン酸化型flt3キナーゼの阻害方法
US10835525B2 (en) 2012-09-26 2020-11-17 Arog Pharmaceuticals, Inc. Method of inhibiting mutant C-KIT
TWI599356B (zh) 2012-09-26 2017-09-21 安羅格製藥有限責任公司 抑制突變型c-kit的方法
US11642340B2 (en) 2012-09-26 2023-05-09 Arog Pharmaceuticals, Inc. Method of inhibiting mutant C-KIT
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
RS58328B1 (sr) * 2014-10-31 2019-03-29 Genoscience Pharma Sas Supstituisani 2,4 diamino-hinolini kao novi antitumorski agensi
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
DK3452465T3 (da) 2016-05-04 2021-02-08 Genoscience Pharma Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
WO2018085292A1 (en) 2016-11-02 2018-05-11 Arog Pharmaceuticals, Inc. Crenolanib for treating flt3 mutated proliferative disorders associated mutations
CN107382984B (zh) * 2017-08-24 2020-07-10 扬州市三药制药有限公司 一种治疗白血病药物的制备方法
CN107382983B (zh) * 2017-08-24 2020-08-07 扬州市三药制药有限公司 一种治疗白血病药物的合成方法
CN110840893A (zh) 2018-12-13 2020-02-28 安罗格制药有限责任公司 含克莱拉尼的药物组合物及其用途
US11471451B2 (en) 2019-08-19 2022-10-18 Arog Pharmaceuticals, Inc. Uses of crenolanib
CN117447376A (zh) * 2019-12-09 2024-01-26 苏州恩华生物医药科技有限公司 连双环结构sigma-1受体抑制剂
WO2022019998A1 (en) * 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
IL300205A (en) * 2020-08-05 2023-03-01 Massachusetts Gen Hospital Salt-inducible kinase inhibitors
US11524006B2 (en) 2020-09-17 2022-12-13 Arog Pharmaceuticals, Inc. Crenolanib for treating TRK kinase associated proliferative disorders
CN113683594B (zh) * 2021-09-07 2022-12-27 曲靖师范学院 一种喹啉-苯并咪唑盐类化合物及其合成方法和应用
JP2023063189A (ja) 2021-10-22 2023-05-09 アログ・ファーマシューティカルズ・インコーポレイテッド 以前の治療に対して再発性/不応性のflt3突然変異増殖性障害を治療するためのクレノラニブ
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
EP1017682A4 (en) 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
UA75055C2 (uk) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
CA2393026A1 (en) * 1999-11-30 2001-06-07 Paul A. Wender Bryostatin analogues, synthetic methods and uses
JP2008002005A (ja) * 2006-06-21 2008-01-10 Shimada Shoji Kk 衣服用パッド

Also Published As

Publication number Publication date
UY27952A1 (es) 2004-03-31
CA2495577A1 (en) 2004-03-11
HK1078571A1 (en) 2006-03-17
EA008448B1 (ru) 2007-06-29
MA27389A1 (fr) 2005-06-01
MXPA05001256A (es) 2005-06-08
PE20050131A1 (es) 2005-03-21
CN1678604A (zh) 2005-10-05
WO2004020431A3 (en) 2004-05-13
EP1594858A2 (en) 2005-11-16
BRPI0313942B8 (pt) 2020-08-04
US7071337B2 (en) 2006-07-04
PA8580301A1 (es) 2005-05-24
CA2495577C (en) 2010-06-15
NZ538427A (en) 2007-04-27
TW200407131A (en) 2004-05-16
EP1594858B1 (en) 2009-10-14
NO20051303L (no) 2005-05-18
IL166832A (en) 2011-03-31
AU2003250499A1 (en) 2004-03-19
AP2005003237A0 (en) 2005-03-31
ECSP055633A (es) 2005-04-18
SI1594858T1 (sl) 2010-01-29
BRPI0313942B1 (pt) 2019-06-04
IS2738B (is) 2011-06-15
DE60329715D1 (de) 2009-11-26
AR041055A1 (es) 2005-04-27
JP4551771B2 (ja) 2010-09-29
KR100816166B1 (ko) 2008-03-21
CR7698A (es) 2007-11-23
DOP2003000694A (es) 2004-02-29
KR20050036984A (ko) 2005-04-20
PL377678A1 (pl) 2006-02-06
KR20070086768A (ko) 2007-08-27
AU2003250499B2 (en) 2009-04-23
ES2333219T3 (es) 2010-02-18
CY1110580T1 (el) 2015-04-29
JP2006501309A (ja) 2006-01-12
HN2003000257A (es) 2004-12-01
MY139357A (en) 2009-09-30
CU23413B7 (es) 2009-09-08
OA12916A (en) 2006-10-13
DK1594858T3 (da) 2009-12-14
IS7660A (is) 2005-01-20
HRP20050191A2 (en) 2005-10-31
ATE445610T1 (de) 2009-10-15
BRPI0313942C1 (pt) 2021-05-25
US20050124599A1 (en) 2005-06-09
WO2004020431A2 (en) 2004-03-11
EA200500174A1 (ru) 2005-08-25
RS20050180A (en) 2007-08-03
CN1319966C (zh) 2007-06-06
GEP20064005B (en) 2006-12-25
HRP20050191A9 (hr) 2013-11-22
HRP20050191B1 (hr) 2013-12-20
PT1594858E (pt) 2009-12-14

Similar Documents

Publication Publication Date Title
BR0313942A (pt) Derivados de benzimidazol úteis como agentes antiproliferativos
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
YU30702A (sh) Novi derivati benzoimidazola, korisni agensi protiv proliferacije
BR0111548A (pt) Derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal
BR9916980A (pt) Derivados bicìclicos substituìdos úteis como agentes anticancerìgenos
BRPI0516453A (pt) derivados de benzoimidazol úteis como agentes antiproliferativos
PT1029853E (pt) Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos
UY25679A1 (es) Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer
BR0008202A (pt) Derivados de quinolin-2-ona substituìdos com heteroarilas úteis como agentes contra o câncer
BR9913138A (pt) Derivados de quinolin-2-ona substituìdos com alquinila úteis como agentes contra o câncer
DK1697370T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
CA2478374A1 (en) N3 alkylated benzimidazole derivatives as mek inhibitors
TW200630361A (en) Integrin antagonists useful as anticancer agents
DE60045508D1 (de) Dalda-analoge und ihre verwendung
BRPI0409230A (pt) formas de dosagem compreendendo ag013736
BR0317433A (pt) Derivados bicìclicos para o tratamento do crescimento celular anormal
BR0214606A (pt) Processos para a preparação de derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal
UY26785A1 (es) Derivados bicíclicos sustituidos para el tratamiento del crecimiento celular anormal
ECSP993260A (es) Derivados biciclicos sustituidos utiles como agentes contra el cancer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2526 DE 04/06/2019 QUANTO AO TITULO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/08/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2683 DE 07-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.